ERBB2 and carcinoma: Because trastuzumab has been shown to dramatically increase overall survival in carcinomas of breast and stomach, there is considerable clinical gain in determining if HER2/neu blockage may be a helpful therapeutic strategy in other human malignancies [4,5].